scout
|Videos|June 7, 2016

Emerging Agents for T790M-Mutant Patients With NSCLC

Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses emerging agents on the horizon for patients with T790M-mutant patients with non-small cell lung cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME